Journal of Dermatology最新文献

{"title":"Author Guidelines","authors":"","doi":"10.1111/1346-8138.70019","DOIUrl":"https://doi.org/10.1111/1346-8138.70019","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e950-e953"},"PeriodicalIF":2.7,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145297169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “A Case of Metastasis of Giant Basal Cell Carcinoma in Oculocutaneous Albinism”","authors":"","doi":"10.1111/1346-8138.17955","DOIUrl":"10.1111/1346-8138.17955","url":null,"abstract":"<p>M. Matsuo, H. Niwa, and H. Iwata, “A Case of Metastasis of Giant basal Cell Carcinoma in Oculocutaneous Albinism,” <i>The Journal of Dermatology</i>, 52, no. 1 (2025): e43–e44, https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17425.</p><p>There were errors in the author byline and the “Conflict of Interest Statement” section for the above article.</p><p>Ken Okamura, Toru Saito, Tamio Suzuki and their affiliations were omitted from the author byline. The correct author byline is shown below:</p><p>Maho Matsuo¹,* Ken Okamura², Toru Saito², Tamio Suzuki², Hirofumi Niwa¹, Hiroaki Iwata¹</p><p>¹Department of Dermatology, Gifu University Graduate School of Medicine</p><p>²Department of Dermatology, Faculty of Medicine, Yamagata University</p><p>The correct CONFLICT OF INTEREST STATEMENT section is shown below:</p><p>Tamio Suzuki is an editor of the <i>Journal of Dermatology</i> and is a coauthor of the current article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication.</p><p>We apologize for the errors.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17955","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145025091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics and Small-Molecule Therapies in Netherton Syndrome: A Comprehensive Review","authors":"Shin Morizane,&nbsp;Tomoyuki Mukai,&nbsp;Ko Sunagawa,&nbsp;Ken-ichi Hasui,&nbsp;Anri Morita,&nbsp;Hayato Nomura,&nbsp;Mamoru Ouchida","doi":"10.1111/1346-8138.17923","DOIUrl":"10.1111/1346-8138.17923","url":null,"abstract":"<p>Netherton syndrome (NS) is a rare congenital ichthyosis caused by loss-of-function mutations in the SPINK5 gene, leading to defective expression of the serine protease inhibitor LEKTI. Dysregulated epidermal protease activity results in impaired skin barrier function and chronic inflammation, accompanied by complex immune profiles. NS patients commonly show activation of the inflammatory axis, centered on IL-17 and IL-36, in the skin and blood, and show a psoriasis-like shift to Th17. Conversely, the immune profile differs depending on the clinical type, with ichthyosis linearis circumflexa type characterized by complement activation and Th2-type allergic responses, and scaly erythroderma type characterized by a type I IFN signature and Th9-type allergic responses. While symptomatic treatments such as emollients and topical corticosteroids have been the mainstay of care, recent advances have opened new therapeutic avenues involving biologic agents and oral small-molecule immunomodulators. This review provides a comprehensive overview of the current clinical landscape and future directions of biologics (e.g., dupilumab, secukinumab, ustekinumab) and small-molecule therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib) in the treatment of NS. Though evidence remains limited to case reports and small series, preliminary data suggest that cytokine-targeted interventions—particularly those inhibiting IL-4, IL-13, IL-17, IL-36, and JAK pathways—may offer tangible clinical benefits. Well-designed clinical trials and mechanistic investigations are crucial to establishing their place in NS management.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1483-1493"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17923","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Cases of Hypertrophic Acne Scar in Japanese Patients Treated With Non-Ablative Fractional Laser","authors":"Kanako Tsunoda,&nbsp;Ayano Watanabe,&nbsp;Miho Hanada,&nbsp;Hiroo Amano","doi":"10.1111/1346-8138.17852","DOIUrl":"10.1111/1346-8138.17852","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e910-e911"},"PeriodicalIF":2.7,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Cutaneous Endometriosis of the Umbilicus","authors":"Francisco Martins,&nbsp;Francisco Mano","doi":"10.1111/1346-8138.17925","DOIUrl":"10.1111/1346-8138.17925","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e908-e909"},"PeriodicalIF":2.7,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended-Interval Dosing of an Immune Checkpoint Inhibitor Following a Complete Response in Melanoma: A Case Report","authors":"Yoshiyuki Matsui,&nbsp;Junji Kato,&nbsp;Tokimasa Hida,&nbsp;Kohei Horimoto,&nbsp;Sayuri Sato,&nbsp;Hisashi Uhara","doi":"10.1111/1346-8138.17899","DOIUrl":"10.1111/1346-8138.17899","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e942-e943"},"PeriodicalIF":2.7,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort","authors":"Yiyi Wang,&nbsp;Jingya Gao,&nbsp;Furong Li,&nbsp;Luyuan Li,&nbsp;Yue Xiao,&nbsp;Hongxiang Hu,&nbsp;Xiya Peng,&nbsp;Min Yang,&nbsp;Dan Hao,&nbsp;Wei Yan,&nbsp;Dengmei Xia,&nbsp;Wei Li","doi":"10.1111/1346-8138.17906","DOIUrl":"10.1111/1346-8138.17906","url":null,"abstract":"<p>Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real-world head-to-head comparisons remain limited. This study aimed to compare the real-world effectiveness and safety of ADA, SEC, and UPA in PsA patients. We conducted a prospective cohort study using data from the PARWCH database. PsA patients treated with ADA, SEC, or UPA were included and followed at baseline, Week 4, Week 12, and Week 24. Skin responses were evaluated using PASI75/90. Joint outcomes—including peripheral and axial arthritis—were assessed with ACR, PsARC, and ASAS criteria. Patient-reported pain, disease activity, and HAQ scores were also recorded. Adverse events (AEs) were monitored throughout treatment. MMRM and GLMM were used to analyze continuous and binary outcomes, respectively. A total of 187 PsA patients were included (SEC: 78; ADA: 66; UPA: 43). All three agents demonstrated comparable effectiveness in improving peripheral joint symptoms (ACR20: SEC vs. ADA, Coef = −0.29, <i>p</i> = 0.62; UPA vs. ADA, Coef = −0.29, <i>p</i> = 0.66) and axial involvement (ASAS20: SEC vs. ADA, Coef = −0.04, <i>p</i> = 0.81; UPA vs. ADA, Coef = −1.05, <i>p</i> = 0.23). UPA and SEC showed significantly greater effectiveness than ADA in improving skin lesions (PASI90: SEC vs. ADA, Coef = 1.84, <i>p</i> = 0.006; UPA vs. ADA, Coef = 1.53, <i>p</i> = 0.04). However, ADA was more effective in relieving pain compared to both UPA (Coef = 2.43, <i>p</i> &lt; 0.001) and SEC (Coef = 1.21, <i>p</i> = 0.02). Over 24 weeks, 85 AEs were reported by 48 patients, with fatigue, rash, upper respiratory tract infection, and pruritus being the most common. No serious AEs occurred. In conclusion, UPA and SEC demonstrated balanced effectiveness across skin and joint domains, while ADA offered superior pain relief. These findings support personalized treatment strategies tailored to the clinical features of PsA patients.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1527-1535"},"PeriodicalIF":2.7,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17906","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis","authors":"Yuki Kuma,&nbsp;Makiko Kido-Nakahara,&nbsp;Yoko Kuba-Fuyuno,&nbsp;Takashi Matsumoto,&nbsp;Yoshinao Oda,&nbsp;Masatoshi Eto,&nbsp;Takeshi Nakahara","doi":"10.1111/1346-8138.17901","DOIUrl":"https://doi.org/10.1111/1346-8138.17901","url":null,"abstract":"<p>Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) therapy and higher EV doses to EV-related skin toxicity (EVST) development. Histopathological findings suggested both direct keratinocyte damage and immune-mediated mechanisms. These insights may improve clinical management of EVST.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1584-1588"},"PeriodicalIF":2.7,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17901","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145297541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ulcerative and Hemorrhagic Bullous Pyoderma Gangrenosum Subsequently Developed Following IgA Vasculitis in a Patient With IgA-λ Multiple Myeloma","authors":"Misaki Kusano,&nbsp;Takako Miura,&nbsp;Yuka Hanami,&nbsp;Toshiyuki Yamamoto","doi":"10.1111/1346-8138.17868","DOIUrl":"10.1111/1346-8138.17868","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e915-e916"},"PeriodicalIF":2.7,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Statin Therapy in KRT16- and KRT17-Associated Palmoplantar Epidermal Differentiation Disorder (Pachyonychia Congenita)","authors":"Sota Itamoto,&nbsp;Wei-Ting Tu,&nbsp;Chih-Yu Chang,&nbsp;Mika Watanabe,&nbsp;Hideyuki Ujiie,&nbsp;Chao-Kai Hsu,&nbsp;Ken Natsuga","doi":"10.1111/1346-8138.17900","DOIUrl":"https://doi.org/10.1111/1346-8138.17900","url":null,"abstract":"<div>\u0000 \u0000 <p>Palmoplantar epidermal differentiation disorder associated with pachyonychia congenita (pEDD-PC) is a rare autosomal dominant skin disorder caused by pathogenic variants in keratin genes, including <i>KRT6A</i>, <i>KRT6B</i>, <i>KRT6C</i>, <i>KRT16</i>, and <i>KRT17</i>. While statins have been reported to alleviate symptoms in <i>KRT6A</i>-pEDD-PC, their efficacy in other subtypes remains unclear. We report six adult patients, including four with <i>KRT17</i> variants and two with <i>KRT16</i> variants, who underwent off-label oral statin therapy. Statins were administered for at least 6 months following dose stabilization. Although the treatment was well tolerated in most cases, no significant clinical improvement in plantar calluses or pain was observed. All patients discontinued therapy due to insufficient efficacy. Our findings indicate that oral statin therapy may offer limited benefit in <i>KRT16</i>/<i>KRT17</i>-pEDD-PC and suggest the potential importance of early intervention and genotype-specific therapeutic strategies.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1608-1611"},"PeriodicalIF":2.7,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145296998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}